Caladrius Biosciences (NASDAQ:CLBS) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.10) by 10 percent. This is a 10 percent decrease over losses of $(0.10) per share from the same period last year.
Related Posts
Black Knight Inc Hires Truist Financial Corp To Explore Sale Of Empower – Sources
Mortgage data vendor Black Knight Inc BKI.N has decided to put its Empower loan origination software business up for sale in an effort to overcome U.S. antitrust concerns over its $13.1 billion proposed
Super Bowl LVI NFTS Continue NFL’s Partnership With Ticketmaster: Here Are The Details
The National Football League is continuing its push into non-fungible tokens with a new collection highlighting Super Bowl LVI and past Super Bowls that were hosted in the city of Los Angeles.
32 Stocks Moving In Friday’s Mid-Day Session
Gainers
CAI International, Inc. (NYSE: CAI) shares jumped 46.4% to $55.86 after the company agreed to a $1.1 billion takeover by Mitsubishi HC Capital Inc.